Grand Pharmaceutical Group Limited (HK:0512) has released an update.
Grand Pharmaceutical Group Limited has achieved a significant milestone with the successful completion of a Phase III clinical trial for its innovative ophthalmic drug, GPN00833, in China. The drug, designed to treat inflammation and pain after cataract surgery, demonstrated superior efficacy and safety compared to a placebo. This advancement bolsters the company’s position in the ENT drug market and underscores its commitment to innovative R&D andglobal marketexpansion.
For further insights into HK:0512 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
